Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
New York, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
The presbyopia market is witnessing steady growth driven by the rising global aging population and increasing prevalence of age-related near vision impairment. Presbyopia market expansion is further supported by growing awareness and higher diagnosis rates. Additionally, the launch of emerging therapies and devices such as Phentolamine (Opus Genetics/Viatris), MicroLine (Pilocarpine Ophthalmic) (Eyenovia), GLK-302 (Glaukos Corporation), CorVision (Intrastromal corneal inlay) (LinkoCare Life Sciences AB), riboflavin/UV-A medical device (RegenSight), and others will further boost the market growth.
Recently published Presbyopia Market Insights report includes a comprehensive understanding of current treatment practices, presbyopia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Presbyopia Market Summary
Discover what is the future market of presbyopia treatment @ https://www.delveinsight.com/sample-request/presbyopia-market
Key Factors Driving the Growth of the Presbyopia Market
Stuti Mahajan, consulting manager at DelveInsight, said that Regulatory approvals of pharmacological presbyopia treatments such as VUITY, QLOSI, VIZZ, and YUVEZZI reflect growing clinical validation and regulatory confidence in non-invasive therapeutic options.
Presbyopia Market Analysis
Learn more about the new drugs for presbyopia @ Presbyopia Treatment Market
Presbyopia Competitive Landscape
Some of the presbyopia drugs and devices under development include Phentolamine (Opus Genetics/Viatris), MicroLine (Pilocarpine Ophthalmic) (Eyenovia), GLK-302 (Glaukos Corporation), CorVision (Intrastromal corneal inlay) (LinkoCare Life Sciences AB), riboflavin/UV-A medical device (RegenSight), and others.
Opus Genetics’ Phentolamine Ophthalmic Solution 0.75% is an advanced investigational treatment for presbyopia that functions as a non-selective alpha-adrenergic antagonist. By reducing iris dilator muscle activity and adjusting pupil size, it improves near vision without directly affecting the ciliary muscle. The therapy is presently under regulatory assessment after the submission of a supplemental NDA in early 2026.
A key differentiator of this candidate is its non-miotic mode of action, which may deliver reliable near-vision benefits without negatively affecting distance vision, a drawback often seen with currently available therapies. Backed by encouraging Phase III clinical data, it demonstrates a favorable safety profile and user-friendly dosing schedule, making it a promising next-generation pharmacologic option in the evolving presbyopia market. Opus Genetics expects a regulatory outcome by the end of 2026.
Linkcore’s CorVision is an innovative bioengineered corneal microlens intended for presbyopia correction. Constructed from collagen, the same natural substance found in the human cornea—it is implanted into a corneal pocket, allowing smooth integration while reducing the risks commonly linked to conventional corneal inlays and more invasive surgical procedures.
The anticipated launch of these emerging presbyopia therapies are poised to transform the presbyopia market landscape in the coming years. As these cutting-edge presbyopia therapies continue to mature and gain regulatory approval, they are expected to reshape the presbyopia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about the top companies in presbyopia market, visit @ Presbyopia Medication
Recent Developments in the Presbyopia Market
What is Presbyopia?
Presbyopia is a common age-related vision condition in which the eye gradually loses its ability to focus on nearby objects, making tasks such as reading, using smartphones, or working on computers more difficult. It typically begins to develop in adults over the age of 40 as the natural lens inside the eye becomes less flexible and the surrounding muscles lose some focusing efficiency. People with presbyopia often experience symptoms such as blurred near vision, eye strain, headaches, and the need to hold reading materials farther away. Although presbyopia is a natural part of aging and not a disease, it can significantly impact daily activities and quality of life. It can be effectively managed with reading glasses, bifocals, contact lenses, or newer prescription eye drops and surgical treatment options.
Presbyopia Epidemiology Segmentation
The presbyopia epidemiology section provides insights into the historical and current presbyopia patient pool and forecasted trends for the leading markets. In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of Presbyopia, with nearly 125,000 cases in 2025.
The presbyopia market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
Download the report to understand presbyopia unmet needs in current treatment @ Presbyopia Treatment Options
Scope of the Presbyopia Market Report
Discover more about the clinical pipeline for presbyopia in 2026 @ Presbyopia Clinical Trials
Table of Contents
Related Reports
Presbyopia Clinical Trial Analysis Pipeline
Presbyopia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
Myopia Market
Myopia Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension Limited, Santen Pharmaceutical, Cloudbreak Therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, and others.
Myopia Clinical Trial Analysis Pipeline
Myopia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myopia companies, including Vyluma, Inc., Sydnexis, Inc., Ocumension Limited, Santen Pharmaceutical, Cloudbreak Therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, and others.
Contact Lenses Market
Contact Lenses Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key contact lenses companies, including Alcon Inc, Cooper Vision Inc, Johnson & Johnson Vision, Bausch Health Companies Inc., HOYA Vision Care Company, Contamac, ZEISS Group, SynergEyes, Menicon Co., Ltd., Gelflex, Orion Vision Group, Solotica, medios, SEED CO. LTD, and others.
Intraocular Lens Market
Intraocular Lens Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key intraocular lens companies, including Johnson & Johnson, HOYA GROUP, Alcon Inc., Carl Zeiss Meditec AG, Bausch & Lomb, Rayner Intraocular Lenses Limited, Eyekon Medical Inc., Lenstec, Inc., HumanOptics AG, STAAR Surgical Company, Aurolab, PhyIOL S.A., Care Group, Tekia Inc., Omni Lens Pvt Ltd, MORCHER® GmbH, Ophtec BV, SIFI S.p.A., Excellent Hi-Care Pvt. Ltd., Hanita Lenses, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.